US 12,329,739 B2
Isoflavonoid compounds and methods for the treatment of cancer
George Jeoffreys, Baulkham Hills (AU); Alison Johnson, Drummoyne (AU); Andrew Heaton, Alexandria (AU); and Ofir Moreno, Poway, CA (US)
Assigned to Aardvark Therapeutic, Inc., San Diego, CA (US)
Filed by Aardvark Therapeutics, Inc., San Diego, CA (US)
Filed on Aug. 1, 2023, as Appl. No. 18/363,328.
Application 18/363,328 is a continuation of application No. 18/154,267, filed on Jan. 13, 2023, abandoned.
Application 18/154,267 is a continuation of application No. 17/023,681, filed on Sep. 17, 2020, granted, now 11,583,514, issued on Feb. 21, 2023.
Application 17/023,681 is a continuation of application No. 16/129,589, filed on Sep. 12, 2018, abandoned.
Application 16/129,589 is a continuation of application No. 15/456,182, filed on Mar. 10, 2017, granted, now 10,105,346, issued on Oct. 23, 2018.
Application 15/456,182 is a continuation of application No. 13/881,609, granted, now 9,663,484, issued on May 30, 2017, previously published as PCT/US2011/058815, filed on Nov. 1, 2011.
Claims priority of provisional application 61/408,972, filed on Nov. 1, 2010.
Prior Publication US 2023/0372287 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/353 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 31/337 (2006.01); A61K 31/555 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61K 47/40 (2006.01); A61P 35/00 (2006.01); C07D 311/58 (2006.01)
CPC A61K 31/353 (2013.01) [A61K 9/0019 (2013.01); A61K 9/5161 (2013.01); A61K 31/337 (2013.01); A61K 31/555 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61K 47/40 (2013.01); C07D 311/58 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol in at least 95% enantiomeric excess, and one or more pharmaceutically acceptable carriers, excipients, auxiliaries, binders and/or diluents.